Neuromuscular Block Clinical Trial
Official title:
Effect of Intravenous Infusion of Magnesium Sulfate Associated or Not to Lidocaine On the Neuromuscular Blockade Induced by Muscle Relaxant Cistracurium
Verified date | December 2015 |
Source | University of Sao Paulo |
Contact | n/a |
Is FDA regulated | No |
Health authority | Brazil: Ethics Committee |
Study type | Interventional |
The magnesium sulfate and lidocaine have been increasingly used alone or in combination
during anesthesia procedure to meet various objectives, such as reduction of pain, use of
smaller anesthetic doses and stabilization of hemodynamic parameters.
These medicines are often used in combination with neuromuscular blocking agents, which may
contribute to the occurrence of residual block in some patients after anesthetic procedures.
It was estimated that only 1-3 % of patients with residual block developing clinically
apparent events. In a small proportion of patients, the consequences of residual blockade
are very serious and even lethal. It is estimated that 40 % of patients with muscle
paralysis come to the post-anesthesia care unit (PACU).
Considering that: (a) magnesium sulfate and lidocaine are showing an increasing number of
applications in various areas of medicine, (b) these medications stand out for their
properties analgesic, anti-inflammatory, anti-arrhythmic, neuroprotective and capable of
reducing the demand of anesthetics and opioids, (c) magnesium sulfate as lidocaine has been
important part of the therapeutic arsenal to control a large number of diseases (d) the
patient surgical surgery or potentially have benefited in particular from its effects, (and)
these drugs have been used routinely in many medical services as well as adjuvants in
anesthesia, (f) previous studies have shown that magnesium sulfate is able to prolong the
duration of neuromuscular blockade by different types of muscle relaxants, with
controversies about its effect on latency (g) the effect of lidocaine on the action of
muscle relaxants in current literature have shown great controversy and (h) do not exist in
the literature studies involving both drugs; the investigators aimed to investigate the
effects of magnesium sulphate infused alone or associated with lidocaine on the
neuromuscular blockade promoted by cisatracurium, as well as evaluate its possible
hemodynamic repercussions. For this purpose the SM was infused in bolus, prior to tracheal
intubation and continuously during the maintenance of general anesthesia; the Lidocaine,
when associated and the Isotonic Solution were used in the same way and timeline as SM. As
secondary objectives it has been proposed to evaluate if the Lidocaine with Magnesium
Sulfate would be able to interfere with the hemodynamic stability of the patients in the
study.
Status | Completed |
Enrollment | 48 |
Est. completion date | September 2015 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 60 Years |
Eligibility |
Before the recruitment of patients, the study was approved by Brazil Platform (a national
and unified basis of research involving human subjects records) and published by the
ClinicalTrials.gov Inclusion Criteria: - ASA I or II - BMI between 18 and 29 Exclusion Criteria: - Use of medications that could affect the neuromuscular blockade such as calcium channel inhibitors, anticonvulsants and lithium carbonate - Presence of neuromuscular, renal or hepatic dysfunction. - Hypermetabolic or hypometabolic states such as fever, infection, and hyperthyroidism or hypothyroidism - Acid-base disorder, congestive heart failure or conductive heart problems, and those who were being treated for cardiac arrhythmias |
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Sao Paulo |
Cardoso LS, Martins CR, Tardelli MA. Effects of intravenous lidocaine on the pharmacodynamics of rocuronium. Rev Bras Anestesiol. 2005 Aug;55(4):371-80. English, Portuguese. — View Citation
Czarnetzki C, Lysakowski C, Elia N, Tramèr MR. Intravenous lidocaine has no impact on rocuronium-induced neuromuscular block. Randomised study. Acta Anaesthesiol Scand. 2012 Apr;56(4):474-81. doi: 10.1111/j.1399-6576.2011.02625.x. Epub 2012 Jan 19. — View Citation
Czarnetzki C, Lysakowski C, Elia N, Tramèr MR. Time course of rocuronium-induced neuromuscular block after pre-treatment with magnesium sulphate: a randomised study. Acta Anaesthesiol Scand. 2010 Mar;54(3):299-306. doi: 10.1111/j.1399-6576.2009.02160.x. E — View Citation
Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology. 2003 May;98(5):1042-8. — View Citation
Doig GS, Simpson F. Randomization and allocation concealment: a practical guide for researchers. J Crit Care. 2005 Jun;20(2):187-91; discussion 191-3. — View Citation
Germano Filho PA, Cavalcanti IL, Barrucand L, Verçosa N. Effect of magnesium sulphate on sugammadex reversal time for neuromuscular blockade: a randomised controlled study. Anaesthesia. 2015 Aug;70(8):956-61. doi: 10.1111/anae.12987. Epub 2015 Apr 1. — View Citation
Ghodraty MR, Saif AA, Kholdebarin AR, Rokhtabnak F, Pournajafian AR, Nikzad-Jamnani AR, Shah A, Nader ND. The effects of magnesium sulfate on neuromuscular blockade by cisatracurium during induction of anesthesia. J Anesth. 2012 Dec;26(6):858-63. doi: 10. — View Citation
Govindarajan R, Shah A, Reddy VS, Parithivel V, Ravikumar S, Livingstone D. Improving the functionality of intra-operative nerve monitoring during thyroid surgery: is lidocaine an option? J Clin Med Res. 2015 Apr;7(4):282-5. doi: 10.14740/jocmr2025w. Epub 2015 Feb 9. — View Citation
Gupta K, Vohra V, Sood J. The role of magnesium as an adjuvant during general anaesthesia. Anaesthesia. 2006 Nov;61(11):1058-63. — View Citation
Habe K, Kawasaki T, Sata T. [A case of prolongation of rocuronium neuromuscular blockade in a pregnant patient receiving magnesium]. Masui. 2014 Jul;63(7):817-9. Japanese. — View Citation
Hans GA, Bosenge B, Bonhomme VL, Brichant JF, Venneman IM, Hans PC. Intravenous magnesium re-establishes neuromuscular block after spontaneous recovery from an intubating dose of rocuronium: a randomised controlled trial. Eur J Anaesthesiol. 2012 Feb;29(2 — View Citation
Hans GA, Defresne A, Ki B, Bonhomme V, Kaba A, Legrain C, Brichant JF, Hans PC. Effect of an intravenous infusion of lidocaine on cisatracurium-induced neuromuscular block duration: a randomized-controlled trial. Acta Anaesthesiol Scand. 2010 Nov;54(10):1192-6. doi: 10.1111/j.1399-6576.2010.02304.x. Epub 2010 Sep 14. — View Citation
Katz RL, Gissen AJ. Effects of intravenous and intra-arterial procaine and lidocaine on neuromuscular transmission in man. Acta Anaesthesiol Scand Suppl. 1969;36:103-13. — View Citation
Kim MH, Oh AY, Han SH, Kim JH, Hwang JW, Jeon YT. The effect of magnesium sulphate on intubating condition for rapid-sequence intubation: a randomized controlled trial. J Clin Anesth. 2015 Nov;27(7):595-601. doi: 10.1016/j.jclinane.2015.07.002. Epub 2015 Aug 25. — View Citation
Kim MH, Oh AY, Jeon YT, Hwang JW, Do SH. A randomised controlled trial comparing rocuronium priming, magnesium pre-treatment and a combination of the two methods. Anaesthesia. 2012 Jul;67(7):748-54. doi: 10.1111/j.1365-2044.2012.07102.x. Epub 2012 Mar 15. — View Citation
Kim SH, So KY, Jung KT. Effect of magnesium sulfate pretreatment on onset and recovery characteristics of cisatracurium. Korean J Anesthesiol. 2012 Jun;62(6):518-23. doi: 10.4097/kjae.2012.62.6.518. Epub 2012 Jun 19. — View Citation
Kopman AF, Kumar S, Klewicka MM, Neuman GG. The staircase phenomenon: implications for monitoring of neuromuscular transmission. Anesthesiology. 2001 Aug;95(2):403-7. — View Citation
Kussman B, Shorten G, Uppington J, Comunale ME. Administration of magnesium sulphate before rocuronium: effects on speed of onset and duration of neuromuscular block. Br J Anaesth. 1997 Jul;79(1):122-4. — View Citation
Loyola YC, Braga Ade F, Potério GM, Sousa SR, Fernandes SC, Braga FS. [Influence of lidocaine on the neuromuscular block produced by rocuronium: study in rat phrenic-diaphragmatic nerve preparation.]. Rev Bras Anestesiol. 2006 Apr;56(2):147-56. Portuguese — View Citation
Matsuo S, Rao DB, Chaudry I, Foldes FF. Interaction of muscle relaxants and local anesthetics at the neuromuscular junction. Anesth Analg. 1978 Sep-Oct;57(5):580-7. — View Citation
McCoy EP, Connolly FM, Mirakhur RK, Loan PB, Paxton LD. Nondepolarizing neuromuscular blocking drugs and train-of-four fade. Can J Anaesth. 1995 Mar;42(3):213-6. — View Citation
Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010 Jul;111(1):120-8. doi: 10.1213/ANE.0b013e3181da832d. Epub 2010 May 4. Review. — View Citation
Nonaka A, Sugawara T, Suzuki S, Masamune T, Kumazawa T. [Pretreatment with lidocaine accelerates onset of vecuronium-induced neuromuscular blockade]. Masui. 2002 Aug;51(8):880-3. Japanese. — View Citation
Rotava P, Cavalcanti IL, Barrucand L, Vane LA, Verçosa N. Effects of magnesium sulphate on the pharmacodynamics of rocuronium in patients aged 60 years and older: A randomised trial. Eur J Anaesthesiol. 2013 Oct;30(10):599-604. doi: 10.1097/EJA.0b013e3283 — View Citation
Shahrami A, Assarzadegan F, Hatamabadi HR, Asgarzadeh M, Sarehbandi B, Asgarzadeh S. Comparison of therapeutic effects of magnesium sulfate vs. dexamethasone/metoclopramide on alleviating acute migraine headache. J Emerg Med. 2015 Jan;48(1):69-76. doi: 10.1016/j.jemermed.2014.06.055. Epub 2014 Sep 30. — View Citation
Staals LM, Driessen JJ, Van Egmond J, De Boer HD, Klimek M, Flockton EA, Snoeck MM. Train-of-four ratio recovery often precedes twitch recovery when neuromuscular block is reversed by sugammadex. Acta Anaesthesiol Scand. 2011 Jul;55(6):700-7. doi: 10.1111 — View Citation
Toft P, Kirkegaard Nielsen H, Severinsen I, Helbo-Hansen HS. Effect of epidurally administered bupivacaine on atracurium-induced neuromuscular blockade. Acta Anaesthesiol Scand. 1990 Nov;34(8):649-52. — View Citation
Ventham NT, Kennedy ED, Brady RR, Paterson HM, Speake D, Foo I, Fearon KC. Efficacy of Intravenous Lidocaine for Postoperative Analgesia Following Laparoscopic Surgery: A Meta-Analysis. World J Surg. 2015 Sep;39(9):2220-34. doi: 10.1007/s00268-015-3105-6. Review. — View Citation
Viby-Mogensen J, Jørgensen BC, Ording H. Residual curarization in the recovery room. Anesthesiology. 1979 Jun;50(6):539-41. — View Citation
Vivancos GG, Klamt JG, Garcia LV. Effects of 2 mg.kg?¹ of intravenous lidocaine on the latency of two different doses of rocuronium and on the hemodynamic response to orotracheal intubation. Rev Bras Anestesiol. 2011 Jan-Feb;61(1):1-12. doi: 10.1016/S0034 — View Citation
* Note: There are 30 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Latency | The latency is computed as the elapsed time to reduce the response of T1 to 5% of the initial contraction force after the infusion of cisatracurium. This outcome meansure was presented in seconds. |
Participants were followed during the anesthetic - surgical procedure, an average of 90 minutes | Yes |
Primary | Clinical Duration | The clinical duration is the elapsed time for T1 recovery = 25% (Dur25%) of the original value of T1 after the infusion of cisatracurium. This outcome meansure was presented in minutes. |
Participants were followed during the anesthetic - surgical procedure, an average of 90 minutes | Yes |
Primary | Recovery Index | The recovery index is the elapsed time between the T1 recovery =25% (Dur25%) and T1 =75% (Dur75%) after the infusion of cisatracurium. This outcome meansure was presented in minutes. |
Participants were followed during the anesthetic - surgical procedure, an average of 90 minutes | Yes |
Primary | Final Recovery Index | The final recovery index is the elapsed time between the T1 recovery = 25% (Dur25%) and T4 / T1 = 80% (TOF = 80%) after the infusion of cisatracurium. This outcome measure was presented in minutes. |
Participants were followed during the anesthetic - surgical procedure, an average of 90 minutes | Yes |
Primary | Total Duration (Dur95%) | The total duration is the elapsed time for T1 recovery of the response to reach 95% of the initial after the infusion of cisatracurium. This outcome measure was presented in minutes. |
Participants were followed during the anesthetic - surgical procedure, an average of 90 minutes | Yes |
Primary | Spontaneous Recovery (T4/T1=90%) | Spontaneous recovery is the elapsed time for the recovery of the TOF (T4 / T1) response to 90% of the original after infusion of cisatracurium. This outcome measure was presented in minutes. |
The participants were followed during the anesthetic - surgical procedure | Yes |
Secondary | MAP - M1 (Mean Arterial Pressure in the Moment 1) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as in the arrival of the patient in the operating room. This time point was named as moment '1'. | This measure of average blood pressure was performed when the patient arrived in the operating room | Yes |
Secondary | MAP - M2 (Mean Arterial Pressure in the Moment 2) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as in the moment immediately before the anesthesia induction. This time point was named as moment '2'. | This measure of average blood pressure was performed immediately before induction of anesthesia | Yes |
Secondary | MAP - M3 (Mean Arterial Pressure in the Moment 3) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as immediately before the start of the infusion of the solution X (magnesium sulfate or isotonic solution) and Y solution (lidocaine or isotonic solution). This time point was named as moment '3'. | This measure of average blood pressure was performed immediately before the start of the infusion of the solution X (magnesium sulfate or isotonic solution) and Y solution (lidocaine or isotonic solution) | Yes |
Secondary | MAP - M4 (Mean Arterial Pressure in the Moment 4) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as in the end of the study solutions infusion.This time point was named as moment '4'. | This measure of average blood pressure was performed five minutes after M3 (in the end of the X and Y solutions infusion) | Yes |
Secondary | MAP - M5 (Mean Arterial Pressure in the Moment 5) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as immediately before the tracheal intubation. This time point was named as moment '5'. | This measure of average blood pressure was performed immediately before the tracheal intubation | Yes |
Secondary | MAP - M6 (Mean Arterial Pressure in the Moment 6) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as one minute after the tracheal intubation. This time point was named as moment '6'. | This measure of average blood pressure was performed one minute after the tracheal intubation | Yes |
Secondary | HR - M1 (Heart Rate in the Moment 1) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The measure of heart rate was recorded and annotated at various times such as in the arrival of the patient in the operating room. This time point was named as moment '1'. | This measure of heart rate was performed when the patient arrived in the operating room | Yes |
Secondary | HR - M2 (Heart Rate in the Moment 2) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as in the moment immediately before the anesthesia induction. This time point was named as moment '2'. | This measure of heart rate was performed immediately before induction of anesthesia | Yes |
Secondary | HR - M3 (Heart Rate in the Moment 3) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as immediately before the start of the infusion of the solution X (magnesium sulfate or isotonic solution) and Y solution (lidocaine or isotonic solution). This time point was named as moment '3'. | This measure of heart rate was performed immediately before the start of the infusion of the solution X (magnesium sulfate or isotonic solution) and Y solution (lidocaine or isotonic solution) | Yes |
Secondary | HR - M4 (Heart Rate in the Moment 4) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as in the end of the study solutions infusion. This time point was named as moment '4'. | This measure of heart rate was performed five minutes after M3 (in the end of the X and Y solutions infusion) | Yes |
Secondary | HR - M5 (Heart Rate in the Moment 5) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as immediately before the tracheal intubation. This time point was named as moment '5'. | This measure of heart rate was performed immediately before the tracheal intubation | Yes |
Secondary | HR - M6 (Heart Rate in the Moment 6) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as one minute after the tracheal intubation. This time point was named as moment '6'. | This measure of heart rate was performed one minute after the tracheal intubation | Yes |
Secondary | MAP - M7a (Mean Arterial Pressure in the Moment 7a) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as 15 minutes after the traqueal intubation. This time point was named as moment '7a'. | This measure of average blood pressure was performed 15 minutes after the traqueal intubation | Yes |
Secondary | MAP - M7b (Mean Arterial Pressure in the Moment 7b) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as 30 minutes after the traqueal intubation. This time point was named as moment '7b'. | This measure of average blood pressure was performed 30 minutes after the traqueal intubation | Yes |
Secondary | MAP - M7c (Mean Arterial Pressure in the Moment 7c) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as 45 minutes after the traqueal intubation. This time point was named as moment '7c'. | This measure of average blood pressure was performed 45 minutes after the traqueal intubation | Yes |
Secondary | MAP - M7d (Mean Arterial Pressure in the Moment 7d) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as 60 minutes after the traqueal intubation. This time point was named as moment '7d'. | This measure of average blood pressure was performed 60 minutes after the traqueal intubation | Yes |
Secondary | MAP - M7e (Mean Arterial Pressure in the Moment 7e) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as 75 minutes after the traqueal intubation. This time point was named as moment '7e'. | This measure of average blood pressure was performed 75 minutes after the traqueal intubation | Yes |
Secondary | MAP - M7f (Mean Arterial Pressure in the Moment 7f) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The mean blood pressure was recorded and annotated at various times such as 90 minutes after the traqueal intubation. This time point was named as moment '7f'. | This measure of average blood pressure was performed 90 minutes after the traqueal intubation | Yes |
Secondary | HR - M7a (Heart Rate in the Moment 7a) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as 15 minutes after the traqueal intubation.This time point was named as moment '7a'. | This measure of heart rate was performed 15 minutes after the traqueal intubation | Yes |
Secondary | HR - M7b (Heart Rate in the Moment 7b) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as 30 minutes after the traqueal intubation. This time point was named as moment '7b'. | This measure of heart rate was performed 30 minutes after the traqueal intubation | Yes |
Secondary | HR - M7c (Heart Rate in the Moment 7c) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as 45 minutes after the traqueal intubation. This time point was named as moment '7c'. | This measure of heart rate was performed 45 minutes after the traqueal intubation | Yes |
Secondary | HR - M7d (Heart Rate in the Moment 7d) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as 60 minutes after the traqueal intubation. This time point was named as moment '7d'. | This measure of heart rate was performed 60 minutes after the traqueal intubation | Yes |
Secondary | HR - M7e (Heart Rate in the Moment 7e) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as 75 minutes after the traqueal intubation. This time point was named as moment '7e'. | This measure of heart rate was performed 75 minutes after the traqueal intubation | Yes |
Secondary | HR - M7f (Heart Rate in the Moment 7f) | In the operating room, patients were cardiovascular, respiratory and body temperature monitored through the Dixtal 2020. The heart rate was recorded and annotated at various times such as 90 minutes after the traqueal intubation. This time point was named as moment '7f'. | This measure of heart rate was performed 90 minutes after the traqueal intubation | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02484651 -
Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade?
|
Phase 4 | |
Completed |
NCT01440933 -
Efficacy of Sugammadex in Magnesium Pretreated Patients
|
Phase 2 | |
Recruiting |
NCT02778945 -
Neuromuscular Blockade for Optimising Surgical Conditions During Spinal Surgery
|
Phase 4 | |
Recruiting |
NCT02966249 -
Dexmetomidine Intrathecally and Intravenously Additionally to Spinal Anaesthesia, in Total Knee Arthroplasty
|
Phase 4 | |
Completed |
NCT02838134 -
Deep Versus Moderate Muscle Relaxation During Laparoscopic Donor Nephrectomy in Enhancing Postoperative Recovery
|
Phase 4 | |
Completed |
NCT03734250 -
D Vitamin Effects on Neuromuscular Blocker Reverse Time
|
||
Not yet recruiting |
NCT03287388 -
MRI Measurement of the Effects of Deep Neuromuscular Blockade on the Abdominal Working Space During Laparoscopy
|
N/A | |
Completed |
NCT01791036 -
Adductor Canal Block In Anterior Cruciate Ligament (ACL) Repair
|
N/A | |
Not yet recruiting |
NCT02648503 -
Deep Neuromuscular Block and Sugammadex Versus Standard of Care on Quality of Recovery in Patient Undergo Elective Laparoscopic Cholecystectomy
|
Phase 4 | |
Completed |
NCT00895609 -
Sugammadex and Neostigmine at Shallow Neuromuscular Blockade
|
Phase 4 | |
Completed |
NCT02320734 -
Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy
|
Phase 4 | |
Recruiting |
NCT05005676 -
Evaluation of the New Acceleromyograph TOF 3D
|
N/A | |
Not yet recruiting |
NCT03460509 -
Reversal With Low Doses of Sugammadex in Patients Undergoing Non-cardiac Surgery
|
Phase 4 | |
Completed |
NCT00828373 -
The Influence of Intravenous Lidocaine on the Action of the Neuromuscular Blocker Rocuronium
|
Phase 4 |